<DOC>
	<DOCNO>NCT01574430</DOCNO>
	<brief_summary>The purpose study determine safety efficacy PDT 30 % verteporfin dose treatment CSC .</brief_summary>
	<brief_title>Study Photodynamic Therapy ( PDT ) Patients With Central Serous Chorioretinopathy ( CSC )</brief_title>
	<detailed_description />
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>patient CSC patient sign ICF patient course CSC le 6 month patient undertake treatment CSC patient porphyria patient allergic verteporfin pregnant nursing woman poor patient compliance sever liver dysfunction dioptric medium opacity make difficult exam fundus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>